Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail)

v3.10.0.1
Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total   $ 0    
Parent Company [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total $ 3,706 300 $ 3,804 $ 3,394
Fortress [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total 0 0 0 300
Checkpoint Therapeutics, Inc [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total 1,000 0 1,000 400
Helocyte [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total 1,500 0 1,521 0
Mustang Therapeutics, Inc [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total 1,000 300 1,075 2,375
Cellvation [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total 0 0 1 0
Caelum Biosciences, Inc. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total 201 0 201 219
Cyprium Therapeutics, Inc. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total 0 0 0 100
Aevitas [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and Development Total $ 5 $ 0 $ 6 $ 0